What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
Steffen T SimonAnne PralongMichael HallekChristoph ScheidUdo HoltickMarco HerlingPublished in: Annals of hematology (2021)
Patients undergoing allogeneic stem cell transplantation (allo-SCT) are given a real chance of cure, but at the same time are confronted with a considerable risk of mortality and of severe long-term impediments. This narrative, non-systematic literature review aims to describe the supportive and palliative care needs of allo-SCT recipients, including long-term survivors or those relapsing or dying after transplantation. It also evaluates the feasibility and effectivity of integrating palliative care early in transplant procedures. In this appraisal of available literature, the main findings relate to symptoms like fatigue and psychological distress, which appear to be very common in the whole allo-SCT trajectory and might even persist many years post-transplantation. Chronic GvHD has a major negative impact on quality of life. Overall, there is a paucity of research on further issues in the context of allo-SCT, like the distress related to the frequently unpredictable post-transplant trajectory and prognosis, as well as the end-of-life phase. First randomized controlled results support the effectiveness of early integration of specialized palliative care expertise into transplant algorithms. Barriers to this implementation are discussed.
Keyphrases
- stem cell transplantation
- palliative care
- advanced cancer
- high dose
- patients undergoing
- systematic review
- multiple sclerosis
- sleep quality
- primary care
- randomized controlled trial
- machine learning
- low dose
- double blind
- young adults
- type diabetes
- early onset
- quality improvement
- risk factors
- placebo controlled
- physical activity
- disease activity
- acute lymphoblastic leukemia